in addition , we can experience fluctuations in net sales as a result of variations in the ordering patterns of our largest customers , which may be driven more by production scheduling and their inventory levels , and less by seasonality . our expenses often do not fluctuate in the same manner as net sales , which may cause fluctuations in operating income that are disproportionate to fluctuations in our revenue . swabcap acquisition on october 6 , 2015 , we acquired all of the outstanding shares of exc holding corp. ( `` exc `` ) , for approximately $ 59.5 million in cash . immediately following the completion of the acquisition of exc we sold certain assets to excelsior medical , llc for a final purchase price including working capital adjustments of $ 29.0 million in cash . we retained all of the assets related to the business of manufacturing and selling the needleless connector disinfection swabcap . the swabcap product enhances our infusion therapy product offering across our existing direct and oem business lines , as well as , open new customer opportunities globally . in 2015 , we signed an exclusive agreement with medline to supply them with swabcaps for their swabflush syringe product used in infusion therapy . the swabcap product is expected to have a minimal impact on earnings per share for the first year , however after one year we expect to see a greater return on invested capital . 25 year-to-year comparisons we present summarized income statement data in item 6. selected financial data . the following table shows , for the three most recent years , the percentages of each income statement caption in relation to revenues . replace_table_token_9_th a portion of our sales is conducted in currencies other than the u.s. dollar , particularly the euro . in 2015 , approximately 13 % of our total revenue was denominated in the euro and translated to the u.s. dollar . significant fluctuations in foreign currency exchange rates , particularly the euro , impact the comparability of our total revenues . in addition to comparing changes in revenue on a u.s. gaap basis , we also compare the changes in revenue from one period to another using constant currency . we provide constant currency information to enhance the visibility of underlying business trends , excluding the effects of changes in foreign currency translation rates . to calculate our constant currency results , we apply the average exchange rate for revenues from the prior year to the current year results . these results should be considered in addition to , not as a substitute for , results reported in accordance with gaap . results on a constant currency basis , as we present them , may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with gaap . comparison of 2015 to 2014 revenues were $ 341.7 million in 2015 , compared to $ 309.3 million in 2014 . on a constant currency basis , revenues would have been $ 350.6 million in 2015 , an increase of $ 41.3 million from 2014. infusion therapy : net infusion therapy sales were $ 244.8 million in 2015 , an increase of $ 28.5 million , or 13 % , from 2014 . on a constant currency basis , net infusion therapy sales would have been $ 249.9 million in 2015 , an increase of $ 33.6 million , or 16 % , from 2014. the increase in infusion therapy sales is primarily due to new customers and higher volume to existing customers . domestic infusion therapy sales were $ 181.8 million in 2015 , an increase of $ 26.4 million , or 17 % , from 2014. the increase in domestic infusion therapy sales was from $ 12.2 million in higher sales to pfizer , and $ 14.2 million in higher direct domestic sales , both due to increased unit sales related to increased utilization and new customers . international infusion therapy sales were $ 63.0 million in 2015 , an increase of $ 2.1 million , or 3 % , from 2014. international infusion therapy sales outside of europe increased $ 3.7 million and were offset by $ 1.6 million in lower european sales due to the decline in the exchange rate of the euro to the u.s. dollar . on a constant currency basis , international infusion therapy sales would have increased $ 7.2 million in 2015 , compared to 2014. critical care : net critical care sales were $ 54.3 million in 2015 , a decrease of $ 0.8 million , or 1.4 % , from 2014. on a constant currency basis , net critical care sales would have been $ 55.2 million in 2015 , an increase of $ 0.2 million from 2014 . 26 the decrease in critical care sales is primarily due the decline in the exchange rate of the euro to the u.s. dollar and lower domestic unit sales . domestic critical care sales were $ 39.2 million in 2015 , a decrease of $ 1.4 million from 2014. international critical care sales were $ 15.1 million in 2015 , an increase of $ 0.6 million , or 4 % , from 2014 primarily due to increased sales outside of europe , partially offset by the effect of the decline in the exchange rate of the euro to the u.s. dollar . story_separator_special_tag the amounts of uncertain tax positions recognized are the largest benefits that have a greater than 50 percent likelihood of being realized upon settlement with the relevant tax authorities . new accounting pronouncements see note 1 of the consolidated financial statements in this annual report on form 10-k. off balance sheet arrangements in the normal course of business , we have agreed to indemnify our officers and directors to the maximum extent permitted under delaware law and to indemnify customers as to certain intellectual property matters related to sales of our products . there is no maximum limit on the indemnification that may be required under these agreements . although we can provide no assurances , we have never incurred , nor do we expect to incur , any liability for indemnification . contractual obligations we have contractual obligations , at december 31 , 2015 , of approximately the amount set forth in the table below . this amount excludes inventory-related purchase orders for goods and services for current delivery . the majority of our inventory purchase orders are blanket purchase orders that represent an estimated forecast of goods and services . we do not have a commitment liability on the blanket purchase orders . since we do not have the ability to separate out blanket purchase orders from non-blanket purchase orders for inventory-related goods and services for current delivery , amounts related to such purchase orders are excluded from the table below . we have excluded from the table below pursuant to asc 740-10-25 ( formerly fin 48 ) , an interpretation of asc 740-10 ( formerly sfas 109 ) , a non-current income tax liability of $ 1.5 million due to the high degree of uncertainty regarding the timing of future cash outflows associated with the liabilities . replace_table_token_10_th forward looking statements various portions of this annual report on form 10-k , including this management 's discussion and analysis of financial condition and results of operations , describe trends in our business and finances that we perceive and state some of our expectations and beliefs about our future . these statements about the future are “ forward looking statements , ” within the meaning of section 27a of the securities act of 1933 , as amended , and section 21e of the securities exchange act of 1934 , as amended , and we identify them by using words such as “ anticipate , ” “ believe , ” “ expect , ” “ estimate , ” “ intend , ” “ plan , ” “ will , ” “ continue , ” “ could , ” “ may , ” and by similar expressions and statements about aims , goals and plans . the forward looking statements are based on the best information currently available to us and assumptions that we believe are reasonable , but we do not intend the statements to be representations as to future results . they include , without limitation , statements about : 31 future growth ; future operating results and various elements of operating results , including future expenditures and effects with respect to sales and marketing and product development and acquisition efforts ; future sales and unit volumes of products ; expected increases and decreases in sales ; deferred revenue ; accruals for restructuring charges , future license , royalty and revenue share income ; production costs ; gross margins ; litigation expense ; future sg & a and r & d expenses ; manufacturing expenses ; future costs of expanding our business ; income ; losses ; cash flow ; amortization ; source of funds for capital purchases and operations ; future tax rates ; alternative sources of capital or financing ; changes in working capital items such as receivables and inventory ; selling prices ; and income taxes ; factors affecting operating results , such as shipments to specific customers ; reduced dependence on current proprietary products ; loss of a strategic relationship ; change in demand ; domestic and international sales ; expansion in international markets , selling prices ; future increases or decreases in sales of certain products and in certain markets and distribution channels ; maintaining strategic relationships and securing long-term and multi-product contracts with large healthcare providers and major buying organizations ; increases in systems capabilities ; introduction , development and sales of new products , including swabcap and integration of exc ; benefits of our products over competing systems ; qualification of our new products for the expedited section 510 ( k ) clearance procedure ; possibility of lengthier clearance process for new products ; planned increases in marketing ; warranty claims ; rebates ; product returns ; bad debt expense ; amortization expense ; inventory requirements ; lives of property and equipment ; manufacturing efficiencies and cost savings ; unit manufacturing costs ; establishment or expansion of production facilities inside or outside of the united states ; planned new orders for semi-automated or fully automated assembly machines for new products ; adequacy of production capacity ; results of r & d our plans to repurchase shares of our common stock ; asset impairment losses ; relocation of manufacturing facilities and personnel ; effect of expansion of manufacturing facilities on production efficiencies and resolution of production inefficiencies ; the effect of costs to customers and delivery times ; business seasonality and fluctuations in quarterly results ; customer ordering patterns and the effects of new accounting pronouncements ; and new or extended contracts with manufacturers and buying organizations ; dependence on a small number of customers ; loss of larger distributors and the ability to locate other distributors ; future sales to and revenues from pfizer and the importance of pfizer to our growth ; effect of the current relationship with pfizer , including its effect on future revenues and our positioning with respect to new product introductions and market share ; and the impact of the pfizer acquisition ; growth of our clave

liquidity and capital resources during 2015 , our cash , cash equivalents and investment securities increased by $ 30.6 million from $ 346.8 million at december 31 , 2014 to $ 377.4 million at december 31 , 2015 . operating activities : our cash provided by operations was $ 54.9 million in 2015 . net income plus adjustments for non-cash net expenses contributed $ 80.7 million to cash provided by operations . net cash used by operations as a result of changes in operating assets and liabilities was $ 25.8 million . the changes in operating assets and liabilities included a $ 20.5 million increase in accounts receivable , an $ 8.3 million increase in inventories , a $ 7.7 million net change in prepaid and deferred income taxes and $ 1.8 million increase in prepaid expenses and other assets , partially offset by a $ 9.4 million increase in accrued liabilities and a $ 3.1 million increase in accounts payable . the increase in accounts receivable was primarily due to higher revenue in the fourth quarter of 2015 compared to the fourth quarter of 2014 and an increase in days sales outstanding . the increase in inventory was primarily due to an increase in forecasted sales and inventory from south africa . the net changes in prepaid and deferred income taxes was primarily due to a loss on the sale of assets to medline and the utilization of an excelsior net operating loss carryover . the $ 9.4 million increase in accrued liabilities was primarily due to restructuring charges accruals , acquisition accruals and accrued compensation and benefits .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources during 2015 , our cash , cash equivalents and investment securities increased by $ 30.6 million from $ 346.8 million at december 31 , 2014 to $ 377.4 million at december 31 , 2015 . operating activities : our cash provided by operations was $ 54.9 million in 2015 . net income plus adjustments for non-cash net expenses contributed $ 80.7 million to cash provided by operations . net cash used by operations as a result of changes in operating assets and liabilities was $ 25.8 million . the changes in operating assets and liabilities included a $ 20.5 million increase in accounts receivable , an $ 8.3 million increase in inventories , a $ 7.7 million net change in prepaid and deferred income taxes and $ 1.8 million increase in prepaid expenses and other assets , partially offset by a $ 9.4 million increase in accrued liabilities and a $ 3.1 million increase in accounts payable . the increase in accounts receivable was primarily due to higher revenue in the fourth quarter of 2015 compared to the fourth quarter of 2014 and an increase in days sales outstanding . the increase in inventory was primarily due to an increase in forecasted sales and inventory from south africa . the net changes in prepaid and deferred income taxes was primarily due to a loss on the sale of assets to medline and the utilization of an excelsior net operating loss carryover . the $ 9.4 million increase in accrued liabilities was primarily due to restructuring charges accruals , acquisition accruals and accrued compensation and benefits .
```    
 Suspicious Activity Report : in addition , we can experience fluctuations in net sales as a result of variations in the ordering patterns of our largest customers , which may be driven more by production scheduling and their inventory levels , and less by seasonality . our expenses often do not fluctuate in the same manner as net sales , which may cause fluctuations in operating income that are disproportionate to fluctuations in our revenue . swabcap acquisition on october 6 , 2015 , we acquired all of the outstanding shares of exc holding corp. ( `` exc `` ) , for approximately $ 59.5 million in cash . immediately following the completion of the acquisition of exc we sold certain assets to excelsior medical , llc for a final purchase price including working capital adjustments of $ 29.0 million in cash . we retained all of the assets related to the business of manufacturing and selling the needleless connector disinfection swabcap . the swabcap product enhances our infusion therapy product offering across our existing direct and oem business lines , as well as , open new customer opportunities globally . in 2015 , we signed an exclusive agreement with medline to supply them with swabcaps for their swabflush syringe product used in infusion therapy . the swabcap product is expected to have a minimal impact on earnings per share for the first year , however after one year we expect to see a greater return on invested capital . 25 year-to-year comparisons we present summarized income statement data in item 6. selected financial data . the following table shows , for the three most recent years , the percentages of each income statement caption in relation to revenues . replace_table_token_9_th a portion of our sales is conducted in currencies other than the u.s. dollar , particularly the euro . in 2015 , approximately 13 % of our total revenue was denominated in the euro and translated to the u.s. dollar . significant fluctuations in foreign currency exchange rates , particularly the euro , impact the comparability of our total revenues . in addition to comparing changes in revenue on a u.s. gaap basis , we also compare the changes in revenue from one period to another using constant currency . we provide constant currency information to enhance the visibility of underlying business trends , excluding the effects of changes in foreign currency translation rates . to calculate our constant currency results , we apply the average exchange rate for revenues from the prior year to the current year results . these results should be considered in addition to , not as a substitute for , results reported in accordance with gaap . results on a constant currency basis , as we present them , may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with gaap . comparison of 2015 to 2014 revenues were $ 341.7 million in 2015 , compared to $ 309.3 million in 2014 . on a constant currency basis , revenues would have been $ 350.6 million in 2015 , an increase of $ 41.3 million from 2014. infusion therapy : net infusion therapy sales were $ 244.8 million in 2015 , an increase of $ 28.5 million , or 13 % , from 2014 . on a constant currency basis , net infusion therapy sales would have been $ 249.9 million in 2015 , an increase of $ 33.6 million , or 16 % , from 2014. the increase in infusion therapy sales is primarily due to new customers and higher volume to existing customers . domestic infusion therapy sales were $ 181.8 million in 2015 , an increase of $ 26.4 million , or 17 % , from 2014. the increase in domestic infusion therapy sales was from $ 12.2 million in higher sales to pfizer , and $ 14.2 million in higher direct domestic sales , both due to increased unit sales related to increased utilization and new customers . international infusion therapy sales were $ 63.0 million in 2015 , an increase of $ 2.1 million , or 3 % , from 2014. international infusion therapy sales outside of europe increased $ 3.7 million and were offset by $ 1.6 million in lower european sales due to the decline in the exchange rate of the euro to the u.s. dollar . on a constant currency basis , international infusion therapy sales would have increased $ 7.2 million in 2015 , compared to 2014. critical care : net critical care sales were $ 54.3 million in 2015 , a decrease of $ 0.8 million , or 1.4 % , from 2014. on a constant currency basis , net critical care sales would have been $ 55.2 million in 2015 , an increase of $ 0.2 million from 2014 . 26 the decrease in critical care sales is primarily due the decline in the exchange rate of the euro to the u.s. dollar and lower domestic unit sales . domestic critical care sales were $ 39.2 million in 2015 , a decrease of $ 1.4 million from 2014. international critical care sales were $ 15.1 million in 2015 , an increase of $ 0.6 million , or 4 % , from 2014 primarily due to increased sales outside of europe , partially offset by the effect of the decline in the exchange rate of the euro to the u.s. dollar . story_separator_special_tag the amounts of uncertain tax positions recognized are the largest benefits that have a greater than 50 percent likelihood of being realized upon settlement with the relevant tax authorities . new accounting pronouncements see note 1 of the consolidated financial statements in this annual report on form 10-k. off balance sheet arrangements in the normal course of business , we have agreed to indemnify our officers and directors to the maximum extent permitted under delaware law and to indemnify customers as to certain intellectual property matters related to sales of our products . there is no maximum limit on the indemnification that may be required under these agreements . although we can provide no assurances , we have never incurred , nor do we expect to incur , any liability for indemnification . contractual obligations we have contractual obligations , at december 31 , 2015 , of approximately the amount set forth in the table below . this amount excludes inventory-related purchase orders for goods and services for current delivery . the majority of our inventory purchase orders are blanket purchase orders that represent an estimated forecast of goods and services . we do not have a commitment liability on the blanket purchase orders . since we do not have the ability to separate out blanket purchase orders from non-blanket purchase orders for inventory-related goods and services for current delivery , amounts related to such purchase orders are excluded from the table below . we have excluded from the table below pursuant to asc 740-10-25 ( formerly fin 48 ) , an interpretation of asc 740-10 ( formerly sfas 109 ) , a non-current income tax liability of $ 1.5 million due to the high degree of uncertainty regarding the timing of future cash outflows associated with the liabilities . replace_table_token_10_th forward looking statements various portions of this annual report on form 10-k , including this management 's discussion and analysis of financial condition and results of operations , describe trends in our business and finances that we perceive and state some of our expectations and beliefs about our future . these statements about the future are “ forward looking statements , ” within the meaning of section 27a of the securities act of 1933 , as amended , and section 21e of the securities exchange act of 1934 , as amended , and we identify them by using words such as “ anticipate , ” “ believe , ” “ expect , ” “ estimate , ” “ intend , ” “ plan , ” “ will , ” “ continue , ” “ could , ” “ may , ” and by similar expressions and statements about aims , goals and plans . the forward looking statements are based on the best information currently available to us and assumptions that we believe are reasonable , but we do not intend the statements to be representations as to future results . they include , without limitation , statements about : 31 future growth ; future operating results and various elements of operating results , including future expenditures and effects with respect to sales and marketing and product development and acquisition efforts ; future sales and unit volumes of products ; expected increases and decreases in sales ; deferred revenue ; accruals for restructuring charges , future license , royalty and revenue share income ; production costs ; gross margins ; litigation expense ; future sg & a and r & d expenses ; manufacturing expenses ; future costs of expanding our business ; income ; losses ; cash flow ; amortization ; source of funds for capital purchases and operations ; future tax rates ; alternative sources of capital or financing ; changes in working capital items such as receivables and inventory ; selling prices ; and income taxes ; factors affecting operating results , such as shipments to specific customers ; reduced dependence on current proprietary products ; loss of a strategic relationship ; change in demand ; domestic and international sales ; expansion in international markets , selling prices ; future increases or decreases in sales of certain products and in certain markets and distribution channels ; maintaining strategic relationships and securing long-term and multi-product contracts with large healthcare providers and major buying organizations ; increases in systems capabilities ; introduction , development and sales of new products , including swabcap and integration of exc ; benefits of our products over competing systems ; qualification of our new products for the expedited section 510 ( k ) clearance procedure ; possibility of lengthier clearance process for new products ; planned increases in marketing ; warranty claims ; rebates ; product returns ; bad debt expense ; amortization expense ; inventory requirements ; lives of property and equipment ; manufacturing efficiencies and cost savings ; unit manufacturing costs ; establishment or expansion of production facilities inside or outside of the united states ; planned new orders for semi-automated or fully automated assembly machines for new products ; adequacy of production capacity ; results of r & d our plans to repurchase shares of our common stock ; asset impairment losses ; relocation of manufacturing facilities and personnel ; effect of expansion of manufacturing facilities on production efficiencies and resolution of production inefficiencies ; the effect of costs to customers and delivery times ; business seasonality and fluctuations in quarterly results ; customer ordering patterns and the effects of new accounting pronouncements ; and new or extended contracts with manufacturers and buying organizations ; dependence on a small number of customers ; loss of larger distributors and the ability to locate other distributors ; future sales to and revenues from pfizer and the importance of pfizer to our growth ; effect of the current relationship with pfizer , including its effect on future revenues and our positioning with respect to new product introductions and market share ; and the impact of the pfizer acquisition ; growth of our clave

